Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Mammostrat: Results of a 1,812-patient study support the prognostic value of Clarient's test for risk-stratifying early-stage, tamoxifen-treated breast cancer, John Bartlett, University of Edinburgh, et al., write in a July 8 article published online by Breast Cancer Research. The researchers found that increased Mammostrat scores were significantly associated with reduced relapse-free survival and overall survival. Clarient expects to launch Mammostrat, gained through its acquisition of Applied Genomics, in the fourth quarter (1"The Gray Sheet" Jan. 4, 2010)